Veracyte Inc VCYT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if VCYT is a good fit for your portfolio.
News
-
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
-
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
-
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
-
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
-
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
-
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
-
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
-
Veracyte Completes Acquisition of C2i Genomics
Trading Information
- Previous Close Price
- $19.48
- Day Range
- $19.16–19.77
- 52-Week Range
- $18.61–30.52
- Bid/Ask
- $7.73 / $25.97
- Market Cap
- $1.45 Bil
- Volume/Avg
- 629,746 / 684,943
Key Statistics
- Price/Earnings (Normalized)
- 25.60
- Price/Sales
- 3.89
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Growth
- Total Number of Employees
- 815
- Website
- https://www.veracyte.com
Comparables
Valuation
|
Metric
|
VCYT
|
ACRS
|
ALEC
|
|---|---|---|---|
Price/Earnings (Normalized) | 25.60 | — | — |
Price/Book Value | 1.35 | 0.54 | 3.04 |
Price/Sales | 3.89 | 2.66 | 4.15 |
Price/Cash Flow | 28.99 | — | — |
Price/Earnings
VCYT
ACRS
ALEC
Financial Strength
|
Metric
|
VCYT
|
ACRS
|
ALEC
|
|---|---|---|---|
Quick Ratio | 4.19 | 3.86 | 3.08 |
Current Ratio | 4.66 | 4.16 | 3.18 |
Interest Coverage | −5,596.07 | — | — |
Quick Ratio
VCYT
ACRS
ALEC
Profitability
|
Metric
|
VCYT
|
ACRS
|
ALEC
|
|---|---|---|---|
Return on Assets (Normalized) | 7.85% | −38.26% | −13.64% |
Return on Equity (Normalized) | 8.41% | −50.08% | −54.21% |
Return on Invested Capital (Normalized) | 7.64% | −49.93% | −44.04% |
Return on Assets
VCYT
ACRS
ALEC
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Pwkjkgkzm | Qkxvm | $209.3 Bil | |
DHR
| Danaher Corp | Qmbkrysf | Fjszc | $182.1 Bil | |
IQV
| IQVIA Holdings Inc | Vnttqxcmq | Mxkrhfj | $42.8 Bil | |
IDXX
| IDEXX Laboratories Inc | Nyqdpgzx | Psqbv | $41.5 Bil | |
A
| Agilent Technologies Inc | Kyxtknlshb | Ktd | $40.4 Bil | |
MTD
| Mettler-Toledo International Inc | Vmyrrlgjg | Vdlbdb | $26.5 Bil | |
ICLR
| Icon PLC | Qmbkxxdy | Bycsvf | $24.8 Bil | |
ILMN
| Illumina Inc | Qdvfqcnp | Mvsmxr | $19.5 Bil | |
WAT
| Waters Corp | Gckgrpmh | Dmgsw | $18.5 Bil | |
LH
| Laboratory Corp of America Holdings | Bwygkrhp | Wvdph | $16.7 Bil |